Cytek Biosciences: Fueling Advancements in Immunotherapy
pharmatechoutlook

Cytek Biosciences: Fueling Advancements in Immunotherapy

Follow Cytek Biosciences on :

Wenbin Jiang, CEO, Cytek BiosciencesWenbin Jiang, CEO
Immune systems – those complex, multi-faceted networks of cells and proteins – are the body’s first line of defense against all manner of invaders. Scientists have been trying to harness the power of the body’s natural defense system to treat disease for over 100 years – with the most rapid advancements in immunotherapy taking place recently. A decade ago, immunotherapy was a predominantly monoclonal drug therapy such as Herceptin or Rituximab. Compare that with today, where scientific advancements have pushed immunotherapy to include a larger list of monoclonal antibodies, cancer vaccines, immune system modulators, and immune system inhibitors including cytokines, small molecules and T-cell therapy. These advances in immunotherapy are possible because of big technological leaps in cell analysis, including molecular technology, gene sequencing, flow cytometry, and cell sorting.

Looking specifically at flow cytometers, these instruments have become a standard tool in immunotherapy research, where their ability to profile several cell subsets in a single sample is routinely used. Flow cytometers identify and quantify different cell types using fluorescent-labeled antibodies that are specific to markers only present on that subpopulation. The more fluorescent-labeled antibodies used to identify these different cellular markers, the deeper the biological insights that can be obtained from one sample – which is especially important when using rare or precious samples from cancer patients.

Representing the first big technological leap in flow cytometry in decades, Cytek Biosciences’ cell analysis systems contain a unique optical design that detects the full spectrum of the many fluorescent particles labeled on each cell. This capability enables the Cytek® Aurora to run 40 color panels, a significant increase in the number of colors per sample, which in turn offers a much more complete picture of all the different cellular players in the immune system. The Cytek Aurora provides scientists in academia, biotechnology and pharmaceuticals with a powerful tool characterizing the immune system’s response and ultimate therapeutic efficacy of their cancer treatment candidate.

“We have taken a fresh look at flow cytometry, starting with an innovative optical design, all the way to super low noise electronics and highly stable fluidics, to power our full-spectrum flow cytometer,” says Dr. Wenbin Jiang, CEO of Cytek Biosciences.

We are committed to advancing the scope, reach and capabilities of flow cytometry, and the only way to accomplish this mission is by developing systems that are powerful and affordable.


The end result is a system with the capability to produce high-quality, highly resolved data in a highly multiplexed format.

Cytek’s innovations have made high parameter flow cytometry possible at an affordable price and are now enabling labs of all sizes to expand on their panels and gain more biological insights from one sample with simplified workflow. Jiang added, “We are committed to advancing the scope, reach and capabilities of flow cytometry, and the only way to accomplish this mission is by developing systems that are powerful and affordable.”

Today, Cytek is recognized for their industry expertise for highly complex multi-parameter flow cytometry. “We have the best understanding of how to check the quality of reagents, how different dyes interact with one another, and how this all affects the performance of multicolor panels,” explains Jiang. Among its users, 30+ color panels are now almost commonplace, which was considered impossible just two short years ago. With Cytek’s full-spectrum flow cytometers, scientists can use 40 cellular markers and beyond per sample to profile the immune system, monitor the effectiveness of immunotherapies, and truly understand the potential for adverse effects like hematological problems, inflammation and other toxicities.

To help its customers accomplish even more on their unique and stateof- the-art cell analyzers, where they are running increasingly complex experiments, Cytek will now start offering reagents. The end goal of this effort is to help shorten the time needed to go from biological question to answer. For example, many research and pharmaceutical labs around the world have quickly shifted toward studying COVID-19 and its resulting immune response for the sake of developing targeted medication and vaccines. “With so little known about this novel coronavirus, there is a need to measure as many immune markers as possible. Our first Cytek cFluorTM reagent was able to help our customers expand their panels and is now being incorporated in multiple different 35-40 color immune monitoring panels,” concludes Jiang.

Immunotherapy continues to be one of the most exciting areas of cancer therapeutics. In a recent documentary titled “Technologies That Enable Immunotherapies,” Cytek and scientists from worldrenowned institutions provide a behind-the-scenes look at the cutting-edge technologies used in the field today. The future of immunotherapy is bright – and companies like Cytek will continue to innovate so that researchers and clinicians around the globe have the tools they need to improve patient treatments.
Share this Article:

Company
Cytek Biosciences

Headquarters
Fremont, CA

Management
Wenbin Jiang, CEO

Description
Cytek Biosciences’ flow cytometry systems represent the first big technological leap in flow cytometry in decades. The full spectrum optics technology onboard enables the ability to use 40 cellular markers and beyond to phenotype cell populations in a heterogeneous sample, providing scientists in academia, biotechnology and pharmaceuticals with a powerful tool for characterizing the immune system’s response to cancer. That information can then be used to improve patient treatments

Cytek Biosciences